| Home : January 2020 : January 24, 2020 News : CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib |
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib |
January 24, 2020
SUZHOU, China, Jan. 24, 2020 /PRNewswire/ --CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient in Australia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with...
https://www.prnewswire.com:443/news-releases/cstone-announces-first-patient-dosed-in-the-global-proof-of-concept-study-of-cs1001-in-combination-with-bayers-regorafenib-300992673.html
|
|
|
 Other Stories |
|
|
|
|
|
|
|
|
|
|
|
